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associated to RCHT. In conclusion, the esophageal BT is an effective alternative for symptomatic relief and improved long-term
dysphagia in advanced or unresectable EC and may improve locoregional control when is used as Boost.
http://dx.doi.org/10.1016/j.rpor.2013.03.031
Image-based 3D treatment planning for vaginal cylinder brachytherapy: Dosimetric effects
F. Casquero1, C. Carvajal 1, E. Hortelano1, A. Gomez-iturriaga1, J. Cacicedo1, I. Muruzabal1, J. Espinoza2,
P. Minguez2, P. Bilbao1
1 Cruces University Hospital, Radiation Oncology, Spain
2 Cruces University Hospital, Physics Radiation, Spain
Purpose. To evaluate, the improvement in accuracy and quality prescription, using three-dimensional image-based treatment
planning and dosimetry for vaginal brachytherapy.
Methods and materials. For three-dimensional planning, ﬁfty-two patients with endometrial or cervical cancer, were simulated
by computed tomography. The bladder, rectum, sigmoid, and small bowel (OARs) were contoured, and prescription dose was
generated for 6 fractions of 450 cGy in 34 patients (65.3%). Associated to external beam radiation therapy in 18 (34.6%) 3 fractions
of 400 cGy. Cylinder diameter was 3 cm in 50 patients (96.2%) and 2.5 cm in 2 (3.8%). Vaginal thickness was estimated with three
3D measures. Dosimetry was calculated prescribing to a line of parallel points to the cylinder surface, including curved area. A
dose-volume histogram analysis was performed in all patients.
Results. The median age was 64 years. Median vaginal thickness was 4.5mm (range 3–5). Dose was prescribed to 3mm (2 p),
4mm (20 p) and 5mm (30 p). In 42.3% (22/52) the prescription depth was different from the standard. If standard prescription
(5mm) is used, there is an overdose of 7% in patients with vaginal thickness of 4mm, and 15% if 3mm. Median DEQ 2Gy per
fraction (OARs) values were: bladder 277 cGy. (135–415), rectum 329 cGy (198–462), and sigma 267 cGy (70–402). The DEQ 2Gy
for exclusive brachytherapy (6 fractions) to (OARs) were: bladder 2115 cGy (1285–3560), rectum 2760 cGy (1536–4244) and sigma
2025cGy (739–3386).
Conclusions. Image-based 3D treatment planning for brachytherapy allows to visualize theprecise placement of cylinder in relation
to vaginal surface, and plan personal treatment with the knowledge of doses at (OARs). And in case of additional external beam
radiotherapy, calculate the DEQ 2Gy per fraction for OARs. In 42% of patients, the prescription dose to 5mm would have been
excessive, with unnecessary overdose to vaginal wall, that might compromise good functional results.
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Purpose. To determine the role of interstitial high-dose-rate brachytherapy (HDR ITB) in themanagement of high risk gynecological
cancer.
Methods. Sixty-two patients with cervical (n=24), endometrial (n=22) and vulvovaginal tumors (n=16) were treated with HDR-ITB
for recurrent tumor after prior radiation (n=14). Unirradiated cases (n=48) were treated with external irradiation (or chemoradi-
ation) and HDR ITB to planned EQD2 doses of 67.6–79.3Gy, and previously irradiated patients received HDR ITB alone to planned
EQD2 doses of 46.7Gy.
Results. With a median follow-up of 3.7 years (range 0.2–10.0), grade ≥3 late events were seen in 7.1% and 16.7% of the previously
irradiated andunirradiated patients, respectively. Grade≥2 bladder eventswere related to younger age (p=0.014), recurrent status
(p=0.025), and 2 cm3 brachytherapy bladder dose (p=0.017) in multivariate analysis. Grade ≥2 rectal events were associated with
vaginal site (p=0.043) and 2 cm3 brachytherapy rectal dose (p=0.001) in multivariate analysis. Five-year locoregional control rates
in previously irradiated cases and unirradiated cases were 55% and 67.5%, respectively. Locoregional control was inversely related
to implant size TV150 (p=0.001) and to brachytherapy EQD2 to CTVD90 (p=0.008) in multivariate analysis. Finally, 5-year overall
survival rates in previously irradiated cases and unirradiated cases were 40% and 57%, respectively.
Conclusions. HDR provides durable control with reasonable toxicity in this patient population with an unfavorable prognosis
and yields long-term disease-free survival in a signiﬁcant percentage of patients. Image-based dosimetric surrogates should be
closely analyzed to minimize long-term toxicity and maximize disease control.
http://dx.doi.org/10.1016/j.rpor.2013.03.033
